Thyroid Eye Disease: Pathogenesis and Treatment

被引：7
|
作者：
Sikder, Shameema [1 ]
Weinberg, Robert S. [2 ]
机构：
[1] Johns Hopkins Univ, Wilmer Eye Inst, Johns Hopkins Hosp, Sch Med,John Hopkins Bayview Med Ctr, Baltimore, MD 21224 USA
[2] Johns Hopkins Bayview, Wilmer Eye Inst, Baltimore, MD USA
来源：
OPHTHALMOLOGICA | 2010年 / 224卷 / 04期
关键词：
Thyroid eye disease; Graves' ophthalmopathy; Graves' disease; GRAVES OPHTHALMOPATHY; MANAGEMENT; RECEPTOR; CLASSIFICATION; EXPRESSION; RITUXIMAB; DEPLETION; TISSUES;
D O I：
10.1159/000260224
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
Thyroid eye disease is common, yet poorly understood. Clarification of the pathogenesis of thyroid eye disease should provide a rational therapeutic approach. This article provides a review of current pathogenic theories for the condition and of the medical management based on those theories. Copyright (C) 2009 S. Karger AG, Basel
引用
收藏
页码：199 / 203
页数：5
相关论文
共 50 条
  • [41] Thyroid eye disease: what is new to know?
    Li, Zhen
    Cestari, Dean M.
    Fortin, Elizabeth
    CURRENT OPINION IN OPHTHALMOLOGY, 2018, 29 (06) : 528 - 534
  • [42] Immunopathogenesis of Thyroid Eye Disease: Emerging Paradigms
    Naik, Vibhavari M.
    Naik, Milind N.
    Goldberg, Robert A.
    Smith, Terry J.
    Douglas, Raymond S.
    SURVEY OF OPHTHALMOLOGY, 2010, 55 (03) : 215 - 226
  • [43] Minimally invasive surgery for thyroid eye disease
    Naik, Milind Neilkant
    Nair, Akshay Gopinathan
    Gupta, Adit
    Kamal, Saurabh
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2015, 63 (11) : 847 - 853
  • [44] Updates on the understanding and management of thyroid eye disease
    Men, Clara J.
    Kossler, Andrea L.
    Wester, Sara T.
    THERAPEUTIC ADVANCES IN OPHTHALMOLOGY, 2021, 13
  • [45] Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity
    Douglas, Raymond S.
    Couch, Steven
    Wester, Sara T.
    Fowler, Brian T.
    Liu, Catherine Y.
    Subramanian, Prem S.
    Tang, Rosa
    Nguyen, Quang T.
    Maamari, Robi N.
    Ugradar, Shoaib
    Hsu, Kate
    Karon, Michael
    Stan, Marius N.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024, 109 (01): : 25 - 35
  • [46] Ocular surface disease in thyroid eye disease: A narrative review
    Rana, Harkaran S. S.
    Akella, Sruti S. S.
    Clabeaux, Carson E. E.
    Skurski, Zachary P. P.
    Aakalu, Vinay K. K.
    OCULAR SURFACE, 2022, 24 : 67 - 73
  • [47] Teprotumumab for the Treatment of Active Thyroid Eye Disease
    Douglas, R. S.
    Kahaly, G. J.
    Patel, A.
    Sile, S.
    Thompson, E. H. Z.
    Perdok, R.
    Fleming, J. C.
    Fowler, B. T.
    Marcocci, C.
    Marino, M.
    Antonelli, A.
    Dailey, R.
    Harris, G. J.
    Eckstein, A.
    Schiffman, J.
    Tang, R.
    Nelson, C.
    Salvi, M.
    Wester, S.
    Sherman, J. W.
    Vescio, T.
    Holt, R. J.
    Smith, T. J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (04): : 341 - 352
  • [48] A New Era in the Treatment of Thyroid Eye Disease
    Patel, Amy
    Yang, Huasheng
    Douglas, Raymond S.
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2019, 208 : 281 - 288
  • [49] Rituximab in the Treatment of Thyroid Eye Disease: A Review
    Ostrowski, Rochella A.
    Bussey, Melissa R.
    Shayesteh, Yasmin
    Jay, Walter M.
    NEURO-OPHTHALMOLOGY, 2015, 39 (03) : 109 - 115
  • [50] Teprotumumab for the treatment of chronic thyroid eye disease
    Ugradar, Shoaib
    Kang, Julia
    Kossler, Andrea L.
    Zimmerman, Erin
    Braun, Jenna
    Harrison, Andrew R.
    Bose, Swaraj
    Cockerham, Kimberly
    Douglas, Raymond S.
    EYE, 2022, 36 (08) : 1553 - 1559
12345